COST-EFFECTIVENESS ANALYSIS OF APIXABAN AND RIVAROXABAN FOR TREATMENT OF ACUTE VENOUS THROMBOEMBOLISM IN CHINA

被引：0
|
作者：
Gu, X. [1 ]
Wu, B. [2 ]
机构：
[1] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Resp, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Med Decis & Econ Grp, Dept Pharm,Renji Hosp, Shanghai, Peoples R China
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.1244
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV98
引用
收藏
页码：A618 / A618
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands
    de Jong, Lisa A.
    Dvortsin, Evgeni
    Janssen, Kristel J.
    Postma, Maarten J.
    [J]. CLINICAL THERAPEUTICS, 2017, 39 (02) : 288 - 302
  • [2] COST-EFFECTIVENESS ANALYSIS FOR APIXABAN IN THE ACUTE TREATMENT AND PREVENTION OF VENOUS THROMBOEMBOLISM IN THE NETHERLANDS
    De Jong, L.
    Dvortsin, E. P.
    Janssen, K. J.
    Postma, M. J.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A651 - A651
  • [3] Apixaban or rivaroxaban in the treatment of acute venous thromboembolism?
    Hellfritzsch, Maja
    Grove, Erik L.
    Adelborg, Kasper
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
  • [4] Cost-effectiveness of rivaroxaban versus apixaban for the initial treatment of venous thromboembolism and extended prevention of recurrences in the UK
    Folkerts, Kerstin
    Broughton, Julie
    Sheikh, Usman
    Mckaig, Sasha
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (11) : 1179 - 1191
  • [5] Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands
    Heisen, Marieke
    Treur, Maarten J.
    Heemstra, Harald E.
    Giesen, Eric B. W.
    Postma, Maarten J.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (08) : 813 - 824
  • [6] Apixaban and Rivaroxaban in Patients With Acute Venous Thromboembolism
    Bott-Kitslaar, Dalene M.
    McBane, Robert D.
    Casanegra, Ana I.
    Houghton, Damon E.
    Froehling, David A.
    Vlazny, Danielle T.
    Ashrani, Aneel A.
    Hodge, David O.
    Vargas, Emily R.
    Bartlett, Matthew A.
    Saadiq, Rayya A.
    Daniels, Paul R.
    Shields, Raymond C.
    Lenz, Charles J.
    Lang, Teresa R.
    Wysokinski, Waldemar E.
    [J]. MAYO CLINIC PROCEEDINGS, 2019, 94 (07) : 1242 - 1252
  • [7] Cost-effectiveness of apixaban compared to other anticoagulants for the acute (6-month) treatment of venous thromboembolism
    Lanitis, T.
    Leipold, R.
    Hamilton, M.
    Rublee, D.
    Quon, P.
    Browne, C.
    Cohen, A.
    [J]. EUROPEAN HEART JOURNAL, 2014, 35 : 1064 - 1064
  • [8] VALIDATION OF THE APIXABAN COST-EFFECTIVENESS MODEL IN PATIENTS WITH VENOUS THROMBOEMBOLISM
    Lanitis, Tereza
    Hamilton, Melissa
    Rublee, Dale
    Browne, Chantelle
    Leipold, Robert
    Quon, Peter
    Masseria, Cristina
    Cohen, Alexander
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (10) : A2087 - A2087
  • [9] Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location
    Janczak, Dawid T.
    Mimier, Malgorzata K.
    McBane, Robert D.
    Kamath, Patrick S.
    Simmons, Benjamin S.
    Bott-Kitslaar, Dalene M.
    Lenz, Charles J.
    Vargas, Emily R.
    Hodge, David O.
    Wysokinski, Waldemar E.
    [J]. MAYO CLINIC PROCEEDINGS, 2018, 93 (01) : 40 - 47
  • [10] Rivaroxaban or apixaban in fragile patients with acute venous thromboembolism
    Trujillo-Santosa, Javier
    Beroizb, Patricia
    Moustafac, Fares
    Alonso, Alicia
    Morejon, Estrella
    Lopez-Reyes, Raquel
    Casado, Ignacio
    Porras, Jose Antonio
    Flores, Katia
    Lopez-Nunez, Juan J.
    Monrealj, Manuel
    [J]. THROMBOSIS RESEARCH, 2020, 193 : 160 - 165
12345